Monica Weldon Consulting, LLC

06/04/2026

Biotechnology is no longer a future industry—it’s a national security, economic growth, and manufacturing imperative.

The U.S. Army’s newly announced biotechnology accelerator initiative signals something much bigger than a government program. It reflects a growing recognition that innovation, advanced computing, AI, biotechnology, and rapid commercialization must move faster and closer together to maintain America’s competitive advantage. The initiative aims to connect private industry, government, and high-performance computing resources to accelerate biotechnology and medical countermeasure development.

For business leaders, investors, manufacturers, and innovators, the message is clear: follow the signal.

The acceleration of biotechnology, advanced manufacturing, and resilient supply chains is creating unprecedented opportunities to bring critical capabilities and production back to the United States. Federal initiatives are increasingly focused on strengthening domestic biotechnology ecosystems, expanding advanced biomanufacturing, and building secure U.S.-based supply chains.

Congratulations to everyone involved in launching this important effort. Programs like these help bridge the gap between breakthrough innovation and real-world deployment while creating opportunities for startups, small businesses, non-traditional contractors, and established industry partners alike.

https://insidedefense.com/insider/army-establishing-technology-accelerator-biotechnology?0=ip_login_no_cache%3D2c00c1acc150ad12a90ab3a7b5c233b4

As Requests for Information (RFIs) and partnership opportunities continue to emerge, now is the time for organizations to engage, collaborate, and position themselves for growth.

If your company is exploring biotechnology, advanced manufacturing, government partnerships, innovation strategy, or federal opportunities and needs support navigating the landscape, feel free to reach out. I’m always happy to discuss how I can help.

05/26/2026

Pandemic preparedness is no longer just a healthcare conversation — it’s a national security, economic resilience, and technology conversation.

I recently wrote about the growing importance of vaccines, biotechnology, AI-powered biosurveillance, and rare-disease innovation in preparing for future biological threats such as Ebola and hantavirus outbreaks.

One area I focused on is the FDA’s Commissioner’s National Priority Voucher Program — an important step forward in accelerating innovation tied to urgent national priorities. During my work supporting the defense industrial base, I advocated for stronger national-priority pathways designed to help accelerate technologies connected to preparedness, health security, and national defense.

The future of biodefense will depend on how quickly government, biotech, pharmaceutical companies, and emerging technologies can work together before crises escalate.

This is not just about treatment anymore.

It’s about prediction, prevention, resilience, and building systems capable of responding faster than the next outbreak spreads.

Read the full blog here: https://www.monicaweldonconsulting.com/blog/americas-next-defense-frontier-viruses-vaccines-ai-and-the-race-to-prevent-the-next-global-crisis


CPE for Chemical, Biological, Radiological and Nuclear Defense

Explore how AI, biotechnology, vaccine innovation, and rare disease research are reshaping pandemic preparedness and national defense. Discover the future of global health security, outbreak prevention, and biotech innovation in a rapidly changing world.

05/01/2026

Thank you to Chemring for the amazing challenge coins.

It’s a pretty cool job when you get to help companies navigate doing business with the government and support programs focused on protecting our country.

These coins represent more than a project. They symbolize innovation, national defense, and the critical work being done to detect and prevent biological and chemical threats before they can harm our communities.

No matter the industry, companies should be thinking long-term about how their work can support national defense objectives, protect innovation, and build safeguards that help prevent adversaries from misusing or stealing technologies created for good.

I’m grateful and excited to support companies working in the national defense sector and to play a small role in helping keep the United States safe.

04/10/2026

The FDA’s new Manufacturing PreCheck Pilot Program is a major opportunity for companies in drug development that are planning where and how to manufacture.

This initiative is designed to help accelerate the buildout of new U.S. pharmaceutical manufacturing facilities by giving selected participants earlier FDA engagement, more direct communication during facility development, and greater regulatory predictability before product application review. The program is focused on strengthening the domestic pharmaceutical supply chain, at a time when more than half of pharmaceuticals distributed in the U.S. are manufactured overseas and only 11% of API manufacturers are U.S.-based.

What stands out is that this is not just a manufacturing initiative, it is also a national security and public health priority. FDA explicitly connects this effort to reducing supply chain vulnerabilities, improving resilience, and helping bring critical medicines and essential manufacturing capacity back to the United States.

For innovators, sponsors, and manufacturing partners, this should be a priority to watch. If you are in the drug development phase and evaluating manufacturing strategy, this is a strong signal that domestic manufacturing readiness, speed, and supply chain resilience are becoming even more important. FDA says the pilot will prioritize facilities that can help address drug shortages, critical medicines, and key supply chain vulnerabilities, especially those using modern technologies and accelerated development approaches.

This is a great opportunity for companies ready to invest in U.S. manufacturing and align early with FDA.

Strengthening the domestic pharmaceutical supply chain

04/03/2026

A strong homeland defense industrial base will not be built by government alone.

This recent Army article highlights why programs like CPE CBRND’s medical readiness and response network matter: they connect data, partnerships, and product development in ways that help the Joint Force respond faster to emerging biological threats. The piece describes how JPL CBRN ET used international partnerships through TARMAC to obtain genomic data quickly, assess existing fielded detection products, and inform ongoing medical countermeasure development through programs like AA-ENBD and RAPID. https://www.army.mil/article/291339/cpe_cbrnd_medical_readiness_and_response_network_protects_the_joint_force_through_information?fbclid=IwdGRleAQ8mQ1leHRuA2FlbQIxMQBzcnRjBmFwcF9pZAo2NjI4NTY4Mzc5AAEeGotmNJKEJ7SSSVjfhTytJmhPdArsD287w9K5jiJzi0cYdNEqokPLuyhQDqM_aem_G37hU3mKHXLyln0z63mIaA

What stands out to me is the bigger lesson for U.S. industry: companies outside the traditional defense base need to get involved now. Building national resilience means bringing more commercial innovators, manufacturers, biotech companies, data platforms, and dual-use technology providers into the conversation—and into the ex*****on.

That is where I focus my work as an independent contractor.

I help companies navigate pathways to engage with programs like these while also building commercialization strategies that do not depend solely on government funding. The goal is not just to win seed funding, but to use that funding strategically to scale capabilities, strengthen business models, and expand real-world impact in both government and commercial markets.

If the United States wants to keep building the capabilities needed to defend the homeland, we need more businesses thinking beyond contracts and toward sustainable, scalable solutions.

Dual-use strategy, commercialization, and mission relevance have to go hand in hand.

U.S. Joint Forces are deployed and stationed across the world in various climates, terrains, and situations. They need to be prepared to protect themsel...

04/01/2026

Congratulations to ARMR Sciences on this major milestone in advancing your fentanyl vaccine program.

Watch the Fox News segment https://www.foxnews.com/video/6392292096112

Through my consulting work with Monica Weldon Consulting, it has been an honor and a pleasure to help provide a roadmap for engaging with the Department of Defense and other federal agencies in support of this important mission.

Innovative solutions like this are exactly what we need in the fight against fentanyl overdose and addiction. Efforts like yours represent the kind of forward-thinking collaboration between science, public health, and national defense that can make a real difference.

Thank you for your leadership, your commitment, and your determination to confront one of the most devastating public health crises facing our country. The work Armor Sciences is doing has the potential to help save lives, support families and communities, and strengthen our nation’s broader response to the fentanyl epidemic.

I am proud to have played a small part in supporting your path forward, and I am grateful for the opportunity to contribute to such meaningful work. Wishing the entire Armor Sciences team continued momentum and success as you move this critical effort forward.

Fox News chief Washington correspondent Mike Emanuel reports on the life-saving impacts the drug could have on ‘America’s Newsroom.’

03/30/2026

It’s hard to put into words what it feels like to see an idea come full circle.

Two years ago, this was a proposal—an idea rooted in strengthening U.S. biomanufacturing, securing our supply chains, and ensuring we could produce critical medicines here at home.

Today, it’s real.

I had the privilege of working at the intersection of industry and government at the DOW/DOD in biotechnology manufacturing, and it was an honor to contribute to efforts like this—where public health, national security, and advanced manufacturing converge.

The newly expanded partnership with the API Innovation Center is a powerful example of what public-private collaboration can achieve. Through this model, federal agencies (including HHS/ASPR via the Defense Production Act) are investing in domestic capability, while industry, academia, and manufacturing partners execute—bringing innovation, scale, and technical expertise together. (API Innovation Center)

Why this matters:

For decades, the U.S. has relied heavily on overseas production for active pharmaceutical ingredients (APIs)—with a majority of essential medicines lacking domestic sources. (API Innovation Center)This created real vulnerabilities—exposed during COVID and ongoing global disruptions.

This initiative changes that.

By combining federal investment with industry ex*****on, the partnership is:• Rebuilding domestic API and finished drug manufacturing• Scaling production of critical medicines like sedatives and cardiovascular drugs• Creating a more resilient, responsive supply chain for national emergencies (ASPR)

Even more powerful—it’s not just one facility. It’s a replicable model: a networked ecosystem of manufacturers, researchers, and suppliers working together to modernize how we produce medicines in the U.S. (Business Wire)

It’s incredibly gratifying to see ideas taken seriously—and implemented at a national scale.

What was once a concept is now shaping policy, infrastructure, and real-world capability.

I’m especially excited (and deeply honored) to be returning to continue this work—supporting efforts to bolster domestic manufacturing, strengthen onshoring of critical medicines, and contribute to the mission of the Nuclear, Chemical, and Biological Programs & Policy office under the Assistant Secretary.

This is exactly why we do the work.

Because when it works—it matters.

🔗

This program expansion includes API and drug product manufacturing, marking first use of DPA Title III funds to support domestic production of a finished medicine.

03/28/2026

I’m excited to share that I’ve started a new freelance, contract advisory engagement with Squire Patton Boggs, LLP as a Senior Advisor.

In this contract role, I’ll be advising on biotechnology manufacturing, industry capabilities, and related regulatory and policy matters, supporting strategic client work on a project basis.

I’m looking forward to contributing to this important work and collaborating with the team at Squire Patton Boggs.